Compare · DXCM vs NEPH
DXCM vs NEPH
Side-by-side comparison of DexCom Inc. (DXCM) and Nephros Inc. (NEPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and NEPH operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 803.3x NEPH ($36.8M).
- Over the past year, DXCM is down 10.6% and NEPH is down 0.9% - NEPH leads by 9.7 points.
- DXCM has hit the wire 26 times in the past 4 weeks while NEPH has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 0 for NEPH).
- Company
- DexCom Inc.
- Nephros Inc.
- Price
- $76.59+5.15%
- $3.42-0.29%
- Market cap
- $29.57B
- $36.8M
- 1M return
- +25.71%
- +9.44%
- 1Y return
- -10.56%
- -0.87%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 26
- 0
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Nephros Inc.
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company operates through three segments: Water Filtration, Pathogen Detection, and Renal Products. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company develops and sells water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. Nephros, Inc. was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest NEPH
- Nephros Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Nephros Announces Financial Results for Quarter Ended March 31, 2026
- SEC Form 10-Q filed by Nephros Inc.
- Amendment: SEC Form 10-K/A filed by Nephros Inc.
- Nephros Schedules First Quarter 2026 Financial Results Conference Call
- Nephros Expands Strategic Focus in Greater New York Market with Dedicated Regional Leadership
- Nephros Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning Expertise
- Nephros Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 4 filed by Banks Robert R. Jr.
- SEC Form 4 filed by Krandel Judy